Clinical Trial

Chronic Kidney Disease (CKD) Platelet Study

Study Description

Chronic Kidney Disease (CKD) Platelet Study

This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration will be two weeks. After recruiting CKD participants the investigator will recruit controls with normal kidney function that will receive only ticagrelor and aspirin for two weeks.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Ticagrelor 90mg

Ticagrelor Pill

Drug - Clopidogrel 75mg

Clopidogrel Pill and a matching placebo to conceal frequency

Drug - Aspirin 81 mg

Aspirin Pill

Additional Information

Official Study Title

A Mechanistic Study in Patients With Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study)

Clinical Trial ID

NCT03649711

ParticipAid ID

dPN7Wa